Is Transesophageal Echocardiography Always Necessary Before Cardioversion of AF Patients After Conventional Anticoagulation Therapy?

  • G. L. Nicolosi
Conference paper


Cardioversion of patients from atrial fibrillation (AF) to normal sinus rhythm is frequently performed to relieve symptoms, improve cardiac performance, and decrease cardioembolic risk. However, the cardioversion procedure itself carries an inherent risk of stroke, presumably due to embolization of extant thrombus or postcardioversion thrombogenesis in the left atrium [1,2].

To decrease this risk, patients with AF of more than 48 h or of unknown duration who undergo cardioversion are conventionally treated with therapeutic anticoagulation [international normalized ratio (INR) 2.0-3.0] for at least 34 weeks before and 4 weeks following cardioversion [1]. Screening for the presence of thrombus in the left atrial or left atrium appendage by transesophageal echocardiography (TEE) is an alternative to routine pre-anticoagulation in candidates for cardioversion of AF [1]. ACC/AHA/ESC guidelines recommend anticoagulation treatment of patients in whom no thrombus is identified with an initial bolus injection of intravenous unfractionated heparin before cardioversion, followed by continuous infusion at a dosage adjusted to prolong the activated partial thromboplastin time to 1.5-2 times the reference control value [1]. Next, the guidelines indicate provision of oral anticoagulation (INR 2.0-3.0) for a period of at least 3-4 weeks, as for patients undergoing elective cardioversion [1]. If a thrombus is identified by TEE, patients should be treated with oral anticoagulation for at least 3-4 weeks before and after restoration of sinus rhythm [1].


Atrial Fibrillation International Normalize Ratio Left Atrial Transesophageal Echocardiography Oral Anticoagulation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fuster V, Ryden LE, Asinger LW (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 22:1852–1923PubMedCrossRefGoogle Scholar
  2. 2.
    Stoddard MF (2000) Risk of thromboembolism in acute atrial fibrillation or atrial flutter. Echocardiography 17:393–405PubMedCrossRefGoogle Scholar
  3. 3.
    Grimm RA (2000) Transesophageal echocardiography-guided cardioversion of atrial fibrillation. Echocardiography 17:383–392PubMedCrossRefGoogle Scholar
  4. 4.
    Becker ER, Culler SD, Shaw LJ, Weintraub WS (2000) Economic aspects of transesophageal echocardiography and atrial fibrillation. Echocardiography 17:407–418PubMedCrossRefGoogle Scholar
  5. 5.
    Labovitz AJ, Bransford TL (2001) Evolving role of echocardiography in the management of atrial fibrillation. Am Heart 1 141:518–527CrossRefGoogle Scholar
  6. 6.
    Klein AL, Grimm RA, Murray D, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF, for the ACUTE Investigators (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344:1411–1420Google Scholar
  7. 7.
    Seidl K, Rameken M, Drogemuller A et al (2002) Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. J Am Coll Cardio139:1436–1442Google Scholar
  8. 8.
    Murray RD, Goodman AS, Lieber EA et al (2000) National use of the transesophageal echocardiographic-guided approach to cardioversion for patients in atrial fibrillation. Am J Cardiol 85:239–244PubMedCrossRefGoogle Scholar
  9. 9.
    Associazione Nazionale Medici CardioligiciOspedalieri. Google Scholar
  10. 10.
    Chug SS, Blackshear JL, Shen W-K, Hammil SC, Gersh BJ (2001) Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 37:371–378CrossRefGoogle Scholar
  11. 11.
    Frykman V, Beerman B, Ryden L, Rosenquist M (2001) Management of atrial fibrillation: discrepancy between guidelines recommendations and actual practice exposes patients to risk for complications. Eur Heart J 22:1954–1959PubMedCrossRefGoogle Scholar
  12. 12.
    Klein AL, Murray DR, Grimm RA (2001) Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 37:691–704PubMedCrossRefGoogle Scholar
  13. 13.
    Chiettin MD, Alpert JS, Armstrong WF (1997) ACC/AHA guidelines for the clinical application of echocardiography: executive summary. J Am Coll Cardiol 29:862–879CrossRefGoogle Scholar
  14. 14.
    Verhorst PMJ, Kamp O, Welling RC, Van Eenige MJ,Visser CA (1997) Transesophageal echocardiographic predictors for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation. Am J Cardiol 79:1355–1359PubMedCrossRefGoogle Scholar
  15. 15.
    Zardo F, Brieda M, Hrovatin E et al (2002) Transesophageal electrical cardioversion of persistent atrial fibrillation: a new approach for an old technology. Ital Heart J 3:354–359PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • G. L. Nicolosi
    • 1
  1. 1.Cardiology Department, ARCAzienda Ospedaliera S. Maria degli AngeliPordenoneItaly

Personalised recommendations